
(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Figure out how to Consolidate All encompassing Practices with a Degree in Brain research - 2
They relied on marijuana to get through the day. But then days felt impossible without it - 3
Experience Unrivaled Sound: Top Speakers You Really want to Hear - 4
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion - 5
21 Incredibly Entertaining Contemplations To Observe Consistently
Step by step instructions to Explore the Close to home Consequence of Cellular breakdown in the lungs
Progress Over Perfection: Lessons From Garment Factories Fighting Heat Stress
Gaza Strip sees flooding after heavy rainfall
How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
Instructions to Upgrade the Security Elements of Your Kona SUV
7 Strange Devices to Make Your Party Stick Out!
Charlotte faith leaders hold interfaith forum on Black and Palestinian solidarity
Thyssenkrupp to suspend electrical steel production at French site
Oldest evidence of human fire-making discovered at site in England












